tldrdailynews.com logo

FDA Panel Raises Concerns Over Sarepta's Gene Therapy for Duchenne Muscular Dystrophy

1 min read
Source: STAT
FDA Panel Raises Concerns Over Sarepta's Gene Therapy for Duchenne Muscular Dystrophy
Photo: STAT
TL;DR

The FDA is holding an advisory panel meeting to review clinical data on Sarepta Therapeutics' experimental gene therapy for Duchenne muscular dystrophy. Many Duchenne patients and their families view the therapy as the best hope for slowing the fatal muscle-wasting disease. The meeting is expected to be contentious and could have a significant impact on the future of the therapy.

Topics:businesshealthcare#advisory-panel#duchenne-muscular-dystrophy#fda#gene-therapy#healthcare#sarepta-therapeutics
Share this article
  1. Tracking the FDA advisory panel on Sarepta's gene therapy  STAT
  2. FDA advisory meeting on DMD gene therapy SRP-9001 livestreams May...  Muscular Dystrophy News
  3. Why Sarepta Therapeutics Stock Faded This Week  The Motley Fool
  4. DisEMBARK? FDA Questions Accelerated Approval Impact On Sarepta's Fully Enrolled Clinical Trial  Pink Sheet
  5. Sarepta's Duchenne Gene Therapy Does Not Have 'Unambiguous Evidence,' FDA Staff Says  Medpage Today

Want the full story? Read the original reporting

Read on STAT